E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteer trial at 4459m to investigate the effect of acetazolamide on the incidence of high altitude pulmonary edema. |
Studie an gesunden Freiwilligen auf 4559m um den Effekt von Acetazolamid auf die Inzidenz des Höhenlungenödems zu untersuchen. |
|
E.1.1.1 | Medical condition in easily understood language |
High altitude pulmonary edema is a non-cardiogenic pulmonary edema. Symptoms are inappropriate dyspnea during exercise, reduced exercise performance, mild fever, orthopnea, pink frothy sputum. |
Das Höhenlungenödem ist ein nicht-kardiales Ödem, das sich durch Atemnot, eine inadäquate Leistungsminderung, leichtes Fieber, Orthopnoe sowie teilweise blutig schaumigen Auswurf äußert. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physical Phenomena [G01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020045 |
E.1.2 | Term | High altitude illness |
E.1.2 | System Organ Class | 100000004863 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does acetazolamide reduce the incidence of high altitude pulmoanry edema after rapid and active ascent to 4559 m? |
Reduziert Acetazolamid die Inzidenz des Höhenlungenödems nach schnellem Aufstieg auf 4559 m? |
|
E.2.2 | Secondary objectives of the trial |
1. Does acetazolamide reduce the height of pulmonary artery pressure after rapid, active ascent to 4559 m? 2. Does acetazolamide reduce the incidence of acute mountain sickness after rapid, active ascent to 4559 m?
|
1. Reduziert Acetazolamid die Höhe des Lungenarteriendruckes nach schnellem Aufstieg auf 4559 m? 2. Reduziert Acetazolamid die Inzidenz der Akuten Bergkrankheit nach schnellem Aufstieg auf 4559 m? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18-64 years - Previous history of high altitude pulmonary edema - Good physical condition - No relevant pathologies upon the pre-examination prior to the study - Written informed consent to participate in the study - Permanent residency below 1000 m - Males and females are included without prioritization - Previous experience in the use of crampons and ice axe |
- Alter: 18-64 Jahre - Höhenlungenödem in der Vorgeschichte - Guter Gesundheitszustand (geistig/körperlich) - Keine klinisch relevanten pathologischen Befunde bei der Voruntersuchung - Freiwillig unterzeichnete Einverständniserklärung nach vollständiger Information bezüglich der Studie - Ansässig / Hauptaufenthaltsort in einer Höhe unter 1000 m - Bezüglich der Geschlechterverteilung gibt es keine Vorgaben und werden Männer und Frauen gleichermaßen berücksichtigt - Erfahrung in der Benutzung von Steigeisen und Pickel |
|
E.4 | Principal exclusion criteria |
- Acute and chronic lung diseases - Conventional systolic blood pressure (average of two measurements) ≥150 mmHg and conventional diastolic blood pressure ≥95 mmHg in untreated or treated subjects - Cardiovascular diseases other than systemic arterial hypertension (coronary heart disease, pulmonary hypertension, heart failure, atrial fibrillation, peripheral artery disease) - Chronic headache / migraine - Diabetes mellitus - Smoking (>6 cigarettes/day) or equivalent nicotine substitutes - Alcohol (>30 g/d) or drug abuse - Obesity (Body Mass Index >30) - Other conditions deemed relevant by the investigator (including liver disease, renal disease, thyroid disorders, pregnancy, lactation) - Sojourn >2000 m within the last 4 weeks before the 1st study day - Drug intake within the last 2 moth before the 1st study day if the drug intake could affect the data quality (eg. corticosteroids) or the safety of the participants (eg. anti-coagulants) - Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation - Blood donation within the last 2 month before the 1st study da |
- Akute und chronische Lungenerkrankungen - Arterielle Hypertonie mit systolischen Blutdruckwerten >150 mmHg und diatolischen Blutdruckwerten >95 mmHg - Weitere kardiovaskuläre Erkrankungen (koronare Herzerkrankung, Herzinsuffizienz, Vorhofflimmern, periphere arterielle Verschlusskrankheit) - Chronischer Kopfschmerz / Migräne - Diabetes mellitus - Weitere Erkrankungen mit Relevanz für die Studie (z.B. Leber-, Nieren- und Schilddrüsenfunktionsstörung, Schwangerschaft, Stillzeit) - Nikotinkonsum (>6 Zigaretten/Tag), Nicorette - Alkoholabusus (>30 g/Tag), Drogenabusus - Adipositas (Body Mass Index >30) - Aufenthalt über 2000 m innerhalb der letzten 4 Wochen vor dem Untersuchungstermin - Medikamenteneinnahme innerhalb der letzten 2 Monate, wenn sie die Probandensicherheit oder die Datenqualität beeinflussen könnte - Allerie / Unverträglichkeit bzgl. Acetazolamid, Sulfonamiden oder weiteren Bestandteile des Studien-Medikaments - Blutspende innerhalb der letzten 2 Monate |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence of high altitude pulmonary edema |
Inzidenz des Höhenlungenödems |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 72 hours at 4559 m |
Nach 72 Stunden auf 4559 m |
|
E.5.2 | Secondary end point(s) |
1. Height of pulmonary artery systolic pressure 2. Incidence of acute mountain sickness |
1. Höhe des systolischen pulmonalarteriellen Druckes 2. Inzidenz der Akuten Bergkrankheit |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 72 hours at 4559 m |
Nach 72 Stunden auf 4559 m |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 14 |